- Home
- WSBF vs CRDF Comparison
WSBF vs CRDF Comparison
Compare WSBF & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- CRDF
- Stock Information
- Founded
- WSBF 1921
- CRDF 1999
- Country
- WSBF United States
- CRDF United States
- Employees
- WSBF N/A
- CRDF N/A
- Industry
- WSBF Savings Institutions
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WSBF Finance
- CRDF Health Care
- Exchange
- WSBF Nasdaq
- CRDF Nasdaq
- Market Cap
- WSBF 269.9M
- CRDF 288.7M
- IPO Year
- WSBF N/A
- CRDF N/A
- Fundamental
- Price
- WSBF $13.42
- CRDF $3.06
- Analyst Decision
- WSBF
- CRDF Strong Buy
- Analyst Count
- WSBF 0
- CRDF 4
- Target Price
- WSBF N/A
- CRDF $12.00
- AVG Volume (30 Days)
- WSBF 36.5K
- CRDF 1.1M
- Earning Date
- WSBF 04-29-2025
- CRDF 05-01-2025
- Dividend Yield
- WSBF 4.46%
- CRDF N/A
- EPS Growth
- WSBF 118.94
- CRDF N/A
- EPS
- WSBF 1.01
- CRDF N/A
- Revenue
- WSBF $135,638,000.00
- CRDF $683,000.00
- Revenue This Year
- WSBF N/A
- CRDF N/A
- Revenue Next Year
- WSBF N/A
- CRDF N/A
- P/E Ratio
- WSBF $13.36
- CRDF N/A
- Revenue Growth
- WSBF 3.74
- CRDF 39.96
- 52 Week Low
- WSBF $10.60
- CRDF $2.01
- 52 Week High
- WSBF $16.86
- CRDF $6.38
- Technical
- Relative Strength Index (RSI)
- WSBF 42.81
- CRDF 32.85
- Support Level
- WSBF $13.29
- CRDF $3.65
- Resistance Level
- WSBF $13.87
- CRDF $3.88
- Average True Range (ATR)
- WSBF 0.32
- CRDF 0.21
- MACD
- WSBF -0.02
- CRDF -0.08
- Stochastic Oscillator
- WSBF 27.16
- CRDF 9.30
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, It operates in two segments: Community Banking and Mortgage Banking. The community banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the community banking segment.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").